Tanja A Stamm1, Berthold Reichardt2, Jochen Zwerina3, Valentin Ritschl1, Valerie Nell-Duxneuner4. 1. Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 2. Burgenländische Gebietskrankenkasse, Eisenstadt, Burgenland, Austria. 3. Ludwig Boltzmann-Institute of Osteology at Hanusch-Hospital of WGKK & Trauma Centre Meidling of AUVA, 1st Medical Department, Hanusch-Hospital, Vienna, Austria. 4. Ludwig Boltzmann Department for Epidemiology of Rheumatic Diseases at Klinikum Peterhof of NOEGKK, Niederösterreichische Gebietskrankenkasse, Sauerhofstraße 9-15, 2500, Baden, Austria. valerie.nell-duxneuner@noegkk.at.
Abstract
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6.1 million (72%) insured people in a 4-year observation period from January 2008 to December 2011. Only patients with first prescriptions of bDMARDs were included. All patients with diagnoses other than RA were excluded. RESULTS: A total of 2906 first prescriptions of bDMARDs were included in the present analysis and 19.35% of RA patients were on bDMARDs in Austria taking into account a prevalence of RA of 0.5%. Tocilizumab showed the longest drug survival after 1 year (73.2%), followed by abatacept which had the longest drug survival after 2 (68.2%) and 3 years (65.2%). The most frequent second bDMARDs switched to were adalimumab (n = 109, 26%), tocilizumab (n = 83, 20%) and etanercept (n = 82, 20%) and 37% of biological DMARDs were prescribed as monotherapy (ranging from 33% with infliximab to 46% with tocilizumab). CONCLUSIONS: Our analysis is based on the largest health care database available in Austria. Tocilizumab and abatacept showed the longest drug survival. Adalimumab, tocilizumab and etanercept were the most frequent DMARDs switched to. Of interest was the high number of bDMARD monotherapies.
BACKGROUND:Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6.1 million (72%) insured people in a 4-year observation period from January 2008 to December 2011. Only patients with first prescriptions of bDMARDs were included. All patients with diagnoses other than RA were excluded. RESULTS: A total of 2906 first prescriptions of bDMARDs were included in the present analysis and 19.35% of RApatients were on bDMARDs in Austria taking into account a prevalence of RA of 0.5%. Tocilizumab showed the longest drug survival after 1 year (73.2%), followed by abatacept which had the longest drug survival after 2 (68.2%) and 3 years (65.2%). The most frequent second bDMARDs switched to were adalimumab (n = 109, 26%), tocilizumab (n = 83, 20%) and etanercept (n = 82, 20%) and 37% of biological DMARDs were prescribed as monotherapy (ranging from 33% with infliximab to 46% with tocilizumab). CONCLUSIONS: Our analysis is based on the largest health care database available in Austria. Tocilizumab and abatacept showed the longest drug survival. Adalimumab, tocilizumab and etanercept were the most frequent DMARDs switched to. Of interest was the high number of bDMARD monotherapies.
Entities:
Keywords:
Arthritis; Biological DMARDs; Drug survival; Epidemiology; Rheumatology
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: Lennart T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek Journal: Ann Rheum Dis Date: 2006-12-11 Impact factor: 19.103
Authors: E Collantes; P Zarco; E Muñoz; X Juanola; J Mulero; J L Fernández-Sueiro; J C Torre-Alonso; J Gratacós; C González; E Batlle; P Fernández; L F Linares; E Brito; L Carmona Journal: Rheumatology (Oxford) Date: 2007-05-27 Impact factor: 7.580
Authors: R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann Journal: Arthritis Rheum Date: 1998-09
Authors: Roy Fleischmann; Michael Schiff; Désirée van der Heijde; Cesar Ramos-Remus; Alberto Spindler; Marina Stanislav; Cristiano A F Zerbini; Sirel Gurbuz; Christina Dickson; Stephanie de Bono; Douglas Schlichting; Scott Beattie; Wen-Ling Kuo; Terence Rooney; William Macias; Tsutomu Takeuchi Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995
Authors: Gerd-Rűdiger Burmester; Alan J Kivitz; Hartmut Kupper; Udayasankar Arulmani; Stefan Florentinus; Sandra L Goss; Suchitrita S Rathmann; Roy M Fleischmann Journal: Ann Rheum Dis Date: 2014-02-18 Impact factor: 19.103
Authors: Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Elisabetta Gerratana; Caterina Palleria; Caterina De Sarro; Ada Vero; Luigi Iannone; Antonia Manti; Emilio Russo; Giovambattista De Sarro; Fabiola Atzeni; Edoardo Spina Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241